Announced
Financials
Sources
Tags
neurological diseases
Friendly
Acquisition
biopharmaceuticals
Pending
United States
Pharmaceuticals
Private Equity
Domestic
Public
Synopsis
Biohaven Pharmaceutical Holding Company Ltd. and Royalty Pharma announced today that Biohaven has sold tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and certain derivative compounds thereof to Royalty Pharma for $100 million. Royalty Pharma has also agreed to purchase $50.0 million in common shares of Biohaven, at a price of $45.00 per share. These transactions are expected to provide sufficient cash to fund operations through the end of 2019.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.